Lynx1 Capital Management LP C4 Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $257 Million
- Q4 2024
A detailed history of Lynx1 Capital Management LP transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 6,852,744 shares of CCCC stock, worth $14.5 Million. This represents 9.58% of its overall portfolio holdings.
Number of Shares
6,852,744
Previous 6,880,527
0.4%
Holding current value
$14.5 Million
Previous $39.2 Million
37.1%
% of portfolio
9.58%
Previous 14.04%
Shares
6 transactions
Others Institutions Holding CCCC
# of Institutions
126Shares Held
63MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$14.8 Million1.75% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$12.9 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$10.3 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$9.65 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.38MShares$9.28 Million0.43% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $104M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...